Randomized phase III study of Standard CHOP(S-CHOP) versus Biweekly CHOP(Bi-CHOP) in aggressive Non-Hodgkin's Lymphoma(JCOG9809)

Randomized phase III study of Standard CHOP(S-CHOP) versus Biweekly CHOP(Bi-CHOP) in aggressive Non-Hodgkin's Lymphoma(JCOG9809) - Randomized phase III study of Standard CHOP(S-CHOP) versus Biweekly CHOP(Bi-CHOP) in aggressive Non-Hodgkin's Lymphoma(JCOG9809)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000036

Enrollment

450

Registered

2005-08-04

Start date

1999-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Hodgkin's lymphoma

Interventions

Chemotherapy:Standard CHOP Chemotherapy:Bi-CHOP(dose intensified CHOP)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Intermediate- or high-grade non-Hodgkin's lymphoma, excluding CTCL, ATL and T-LbL (Working Formulation) (2)Ann Arbor stage: II, III, IV (3)No prior chemotherapy or radiotherapy (4)Age: 15 to 69 (5)PS: 0, 1, 2 (6)WBC >= 3,000 /mm3, ANC >= 1,200 /mm3, Platelet >= 75,000 /mm3 (7)GOT/GPT = 50% (10)PaO2 >= 65 mmHg (11)Written informed consent

Exclusion criteria

Exclusion criteria: (1)uncontrolable diabetes mellitus (2)severe complication (infection, heart failure, renal failure, liver failure, etc) (3)anamnesis of heart disease (4)acute or chronic hepatitis, liver chirrosis and portal hypertension (5)synchronous or metachronous malignancy (6)sever plumonary dysfunction (7)CNS invasion (8)HIV positive (9)HBs-Ag positive (10)HCV-Ab positive

Design outcomes

Primary

Measure	Time frame
Progression free survival	—

Secondary

Measure	Time frame
overall survival, complete remission rate, toxicity	—

Countries

Japan

Contacts

Public ContactKen Ohmachi, MD

JCOG9809 Coordinating Office Department of Medicine, Hematology/Oncology, Tokai university

JCOG_sir@ml.jcog.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026